LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY

被引:28
作者
Tan, Nikolle W. [1 ]
Ohno-Matsui, Kyoko [2 ]
Koh, Hyoung J. [3 ]
Nagai, Yoshimi [4 ]
Pedros, Montse [5 ]
Freitas, Rita L. [6 ]
Macfadden, Wayne [6 ]
Lai, Timothy Y. [7 ]
机构
[1] Mt Elizabeth Novena Specialist Ctr, Eye Surg Novena, Singapore, Singapore
[2] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan
[3] Yonsei Univ, Coll Med, Severance Hosp, Dept Ophthalmol,Inst Vis Res, Seoul, South Korea
[4] Kansai Med Univ, Dept Ophthalmol, Hirakata, Osaka, Japan
[5] IMS Hlth Spain, RWE, Barcelona, Spain
[6] Novartis Pharma AG, Basel, Switzerland
[7] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China
来源
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2018年 / 38卷 / 11期
关键词
RADIANCE; myopic choroidal neovascularization; ranibizumab; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED CLINICAL-TRIAL; ANTI-VEGF THERAPY; PATHOLOGICAL MYOPIA; INTRAVITREAL BEVACIZUMAB; VISUAL-ACUITY; FOLLOW-UP; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; PROGNOSTIC-FACTORS;
D O I
10.1097/IAE.0000000000001858
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate long-term efficacy and safety of ranibizumab for treatment of myopic choroidal neovascularization (mCNV) in clinical practice. Methods: Noninterventional, retrospective cohort study of East-Asian patients previously treated with ranibizumab during the RADIANCE trial. Forty-one patients who completed the RADIANCE trial were followed-up for up to 48 months (post-RADIANCE observation period). Outcome measures were best-corrected visual acuity changes from baseline (assessed at RADIANCE trial initiation), mCNV recurrences, and ocular adverse events. Results: Mean visual gain from baseline best-corrected visual acuity (56.5 +/- 12.1 letters) (20/80) was significant at 12 months (+ 14.3 +/- 11.4 letters, n = 40, P < 0.0001), 24 months (+10.4 +/- 22.3 letters, n = 31, P = 0.0143), 30 months (+11.0 +/- 22.4 letters, n = 29, P = 0.0134), 42 months (+12.9 +/- 20.9 letters, n = 25, P = 0.0051), and 48 months (+16.3 +/- 18.7, n = 16, P = 0.0034). Of the 16 patients who completed 48 months of follow-up, 63% gained >= 10 letters and 13% lost >= 10 letters. Over the post-RADIANCE observation period, 83% of patients required no further treatment for mCNV, 10% experienced mCNV recurrences, and 12% experienced a nonserious ocular adverse event. Patients who required additional treatment for mCNV received a mean of 5.0 (SD 5.9, range 1.0-18.0) ranibizumab injections. Conclusion: Best-corrected visual acuity gained at the end of the RADIANCE trial was sustained over additional 36 months of follow-up. Few patients required further treatment and no new safety concerns were observed.
引用
收藏
页码:2228 / 2238
页数:11
相关论文
共 41 条
[1]  
Arnold J, 2001, OPHTHALMOLOGY, V108, P841
[2]  
AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
[3]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[4]   Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab [J].
Cohen, Salomon Y. ;
Nghiem-Buffet, Sylvia ;
Grenet, Typhaine ;
Dubois, Lise ;
Ayrault, Sandrine ;
Fajnkuchen, Franck ;
Delahaye-Mazza, Corinne ;
Quentel, Gabriel ;
Tadayoni, Ramin .
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2015, 59 (01) :36-42
[5]   Current and emerging treatment options for myopic choroidal neovascularization [J].
El Matri, Leila ;
Chebil, Ahmed ;
Kort, Fedra .
CLINICAL OPHTHALMOLOGY, 2015, 9 :733-744
[6]   Ranibizumab Treatment for Choroidal Neovascularization Secondary to Causes Other than Age-Related Macular Degeneration with Good Baseline Visual Acuity [J].
Erol, Muhammet Kazim ;
Ozdemir, Ozdemir ;
Coban, Deniz Turgut ;
Ceran, Basak Bostanci ;
Bulut, Mehmet .
SEMINARS IN OPHTHALMOLOGY, 2014, 29 (02) :108-113
[7]  
European Medicines Agency, 2015, LUC SUMM PROD CHAR L
[8]   Progression of Myopic Maculopathy after Treatment of Choroidal Neovascularization [J].
Farinha, Claudia L. ;
Baltar, Alda S. ;
Nunes, Sandrina G. ;
Figueira, Joao P. ;
Pires, Isabel A. ;
Cachulo, Maria L. ;
Silva, Rufino M. .
OPHTHALMOLOGICA, 2014, 231 (04) :211-220
[9]   Long-Term Follow-Up of Myopic Choroidal Neovascularization Treated with Ranibizumab [J].
Franqueira, Nuno ;
Luz Cachulo, M. ;
Pires, Isabel ;
Fonseca, Pedro ;
Marques, Ines ;
Figueira, Joao ;
Silva, Rufino .
OPHTHALMOLOGICA, 2012, 227 (01) :39-44
[10]   Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results [J].
Freitas-da-Costa, Paulo ;
Pinheiro-Costa, Joao ;
Carvalho, Beatriz ;
Falcao, Manuel ;
Brandao, Elisete ;
Falcao-Reis, Fernando ;
Carneiro, Angela .
OPHTHALMOLOGICA, 2014, 232 (01) :57-63